Albers, LJ, Reist, C, Helmeste, D et al (1996) Paroxetine shifts imipramine metabolism. Psychiatry Research; 59: 189–96.
Bakish, D, Hooper, CL, West, DL et al (1995) Moclobemide and specific serotonin reuptake inhibitor combination treatment of resistant anxiety and depressive disorders. Human Psychopharmacology; 10: 105–9.
Blier, P, Saint-Andre, E, Hebert, C et al (2007) Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. International Journal of Neuropsychopharmacology; 10: 41–50.
Brosen, K (2004) Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie; 59: 5–12.
Debonnel, G, Saint-André, É, Hébert, C et al (2007) Differential physiological effects of a low dose and high doses of venlafaxine in major depression. International Journal of Neuropsychopharmacology; 10: 51–61.
Dodd, S, Horgan, D, Malhi, GS et al (2005) To combine or not to combine? A literature review of antidepressant combination therapy. Journal of Affective Disorders; 89: 1–11.
Draper, AJ, Madan, A, Parkinson, A (1997) Inhibition of coumarin 7-hydroxylase activity in human liver microsomes. Archives of Biochemistry and Biophysics; 341: 47–61.
Ebert, D, Albert, R, May, A et al (1995) Combined SSRI-RIMA treatment in refractory depression. Safety data and efficacy. Psychopharmacology; 119: 342–4.
Gillman, PK (2004) Moclobemide and the risk of serotonin toxicity (or serotonin syndrome). Central Nervous System Drug Reviews; 10: 83–5.
Gillman, PK (2006) A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action. Biological Psychiatry; 59: 1046–51.
Gillman, PK (2007) Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. British Journal of Pharmacology; 151: 737–48 [Free full text].
Hawley, CJ, Quick, SJ, Ratnam, S et al (1996) Safety and tolerability of combined treatment with moclobemide and SSRIs – a systematic study of 50 patients. International Clinical Psychopharmacology; 11: 187–91.
Holt, A, Berry, MD, Boulton, AA (2004) On the binding of monoamine oxidase inhibitors to some sites distinct from the MAO active site, and effects thereby elicited. Neurotoxicology; 25: 251–66.
Ingelman-Sundberg, M (2005a) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics Journal; 5: 6–13 [Free full text].
Ingelman-Sundberg, M, Rodriguez-Antona, C (2005b) Pharmacogenetics of drug-metabolizing enzymes: implications for a safer and more effective drug therapy. Philosophical Transactions of the Royal Society of London. Series B: Biological Sciences; 360: 1563–70.
Joffe, RT, Bakish, D (1994) Combined SSRI-moclobemide treatment of psychiatric illness. Journal of Clinical Psychiatry; 55: 24–5.
Nelson, JC, Mazure, CM, Jatlow, PI et al (2004) Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biological Psychiatry; 55: 296–300.
Palaniyappan, L, Insole, L, Ferrier, N (2009) Combining antidepressants: a review of evidence. Advances in Psychiatric Treatment; 15: 90–9.
Preskorn, S, Flockhart, D (2006) 2006 Guide to psychiatric drug interactions. Primary Psychiatry; 13: 35–64.
Sim, SC, Ingelman-Sundberg, M (2006) The human cytochrome P450 Allele Nomenclature Committee Web site: submission criteria, procedures, and objectives. Methods in Molecular Biology; 320: 183–91.
Whyte, IM, Dawson, AH, Buckley, NA (2003) Relative toxicity of venlafaxine and selective serotonin reuptake inhibitors in overdose compared to tricyclic antidepressants. Quarterly Journal of Medicine; 96: 369–74 [Free full text].